|
Table 2: Main model inputs in the heterozygous familial hypercholesterolemia subpopulation. |
||
|
Description |
Base-case value |
Source |
|
Baseline characteristics |
|
|
|
Mean age (years) |
51.0 |
RUTHERFORD-2 trial18 |
|
Proportion of females (%) |
42.2 |
RUTHERFORD-2 trial18 |
|
Mean LDL-C (mg/dL) |
217.8 |
Benn et al. 201219 |
|
Concomitant use of ezetimibe (%) |
62.0 |
RUTHERFORD-2 trial18 |
|
Distribution among initial health state |
|
Derived from Borissov et al.15 which used data collected in the RUTHERFORD-2 trial18 |
|
Post-MI (%) |
35.56 |
|
|
Post-IS (%) |
3.33 |
|
|
oASCVD (%) |
61.11 |
|
|
Baseline annual CV event rate* |
7.99 |
Derived from Borissov et al.15 |
|
Relative reduction of LDL-C with evolocumab (%) |
59.2 |
RUTHERFORD-2 trial18 |
|
LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; IS = ischemic stroke; oASCVD = other atherosclerotic cardiovascular disease; CV = cardiovascular. * Represents the rate per 100 patient-years under standard of care, calculated as -LN (1 - 0.55) / 10; where LN is natural logarithm and 0.55 is the predicted 10-year risk for mean age of 51.16 years and mean LDL-C level of 155.46 mg/dL. |
||